Document Detail


Is acute myeloid leukemia a liquid tumor?
MedLine Citation:
PMID:  23280377     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Extramedullary manifestations of acute myeloid leukemia (AML) were described as early as the 19th century. However, the incidence, clinical significance and pathobiology of extramedullary AML remain ill defined. We reviewed case reports, retrospective case series, pilot studies and imaging studies of extramedullary leukemia (EML) to determine its frequency, characteristics, clinical presentation and significance. EML precedes or accompanies development of AML and occurs during or following treatment, even during remission. Although imaging studies are rarely conducted and the true incidence of EML has yet to be verified, authors have reported several estimates based on retrospective and autopsy studies. The incidence of EML in patients with AML of all ages is estimated to be about 9% and EML in children with AML was detected in 40% of patients at diagnosis. The combination of positron emission tomography and computed tomography were the most sensitive and reliable techniques of detecting and monitoring EML. Based on our literature review, the frequency of EML is likely underreported. The well-documented nature of EML in patients with AML suggests that AML can manifest as a solid tumor. The extent to which EML accompanies AML and whether EML is derived from bone marrow are unknown. Furthermore, questions remain regarding the role of the microenvironment, which may or may not facilitate the survival and proliferation of EML, and the implications of these interactions with regard to minimal residual disease, tumor cell quiescence and relapse. Therefore, prospective studies of detection and characterization of EML in patients with AML are warranted.
Authors:
Maro Ohanian; Stefan Faderl; Farhad Ravandi; Naveen Pemmaraju; Guillermo Garcia-Manero; Jorge Cortes; Zeev Estrov
Related Documents :
22938417 - Chemopreventive potential of annona muricata l leaves on chemically-induced skin papill...
8868097 - Diagnosis and management of adrenal tumors.
15024897 - Hyperaldosteronism and pheochromocytoma: new tricks and tests.
20874817 - Severe polyuria after the resection of adrenal pheochromocytoma.
2859127 - Inhibitory effects of glutathione level-raising agents and d-alpha-tocopherol on ornith...
8159647 - Assessment of ki-67-derived tumor proliferative activity in colorectal adenocarcinomas.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review     Date:  2013-02-04
Journal Detail:
Title:  International journal of cancer. Journal international du cancer     Volume:  133     ISSN:  1097-0215     ISO Abbreviation:  Int. J. Cancer     Publication Date:  2013 Aug 
Date Detail:
Created Date:  2013-05-22     Completed Date:  2013-07-25     Revised Date:  2014-08-05    
Medline Journal Info:
Nlm Unique ID:  0042124     Medline TA:  Int J Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  534-43     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 UICC.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cell Proliferation
Cell Survival
Humans
Leukemia, Myeloid, Acute / pathology*,  physiopathology*
Myeloproliferative Disorders / pathology,  physiopathology
Prognosis
Recurrence
Sarcoma, Myeloid / diagnosis,  pathology*,  physiopathology*
Treatment Outcome
Tumor Microenvironment
Grant Support
ID/Acronym/Agency:
CA016672/CA/NCI NIH HHS; P30 CA016672/CA/NCI NIH HHS
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  How quickly do physicians adopt new drugs? The case of second-generation antipsychotics.
Next Document:  Reliability of Objective Voice Measures of Normal Speaking Voices.